QLGN - Qualigen Therapeutics, Inc. Operating income before deduction of amortization

Graphic logo of Qualigen Therapeutics, Inc. (QLGN)

By combining diagnostic test sales with the development of oncology drugs, Qualigen Therapeutics (QLGN) is stabilizing its cash flow. The operating profit (EBIT) trend confirms this dynamic, where shows the value of this parameter. The strategy relies on the AS1411 platform, which locks clinics into its protocols, although the focus on anti-tumor developments maintains high binary risks for capital.

QLGN - Qualigen Operating profit before deduction of amortization over the range 07/04/2022 - 11/11/2026

Summary analytical data breakdowns for Qualigen Therapeutics, Inc. (QLGN)

- stock price and consensus target price:
Price Chart Qualigen Corp|QLGN - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Qualigen Therapeutics|QLGN - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Qualigen Therapeutics|QLGN - Company Net Assets|Market Capitalization to Book Value Ratio qualigeninc.com|QLGN - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Qualigen Therapeutics|QLGN - Long-Term Debt to Equity|Short-Term Indebtedness to Equity Qualigen Therapeutics Inc|QLGN - Company Total Debt|Debts to Book Capitalization Qualigen Therapeutics|QLGN - Company Long-Term Debts|Company Short-Term Debts Qualigen Therapeutics|Quick Liquidity qualigeninc.com
- earnings and market ratios statistics:
QLGN - Net Profit|Company Profit Forecast Qualigen Therapeutics|QLGN - P/E Multiple|Forward Price to Earnings Multiple qualigeninc.com|QLGN - PEG Multiple|Company Value to EBITDA Qualigen Therapeutics|QLGN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Qualigen Therapeutics|QLGN - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months qualigeninc.com|QLGN - Net earnings per share growth this year|Projected earnings per share increase next year Qualigen Therapeutics
Fundamental company valuation:QLGN (Qualigen Corp)
Signature product of Qualigen Therapeutics, Inc.

This indicator measures real cash flow from operating activities, excluding non-cash charges and depreciation to assess the actual solvency of the business. By analyzing the operating financial result, an investor can see the efficiency of Qualigen Therapeutics (QLGN) transitioning toward organic growth and targeted licensing agreements, which confirms the viability of the company's core without relying on aggressive acquisitions.

Who Qualigen Therapeutics competes with

Gilead Corp - Profit before payment of interest, taxes and amortization|Cidara Therapeutics, Inc. - Operating profit EBITDA|Operating income before deduction of amortization novavax.com NVAX|CureVac (CVAC) - Profit before payment of interest, taxes and amortization|Valneva Corp - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization VIR|Operating profit EBITDA TPOXX|Profit before payment of interest, taxes and amortization Emergent BioSolutions (EBS)|Operating income before deduction of amortization ateapharma.com|Profit before payment of interest, taxes and amortization Invivyd IVVD|Operating profit before depreciation charges Enanta Pharmaceuticals Inc.|INO: Operating profit before deduction of amortization|HLVX - Operating profit EBITDA|KLRS: Operating profit EBITDA|Dyadic International, Inc. (DYAI) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NanoViricides Inc.|Profit before payment of interest, taxes and amortization TLPH|Operating profit EBITDA COCP|Operating income before deduction of amortization trawspharma.com|Operating profit EBITDA DWTX (Dogwood Therapeutics)|Operating profit before depreciation charges AlloVir Inc|VBI Vaccines Inc - Operating profit EBITDA|Profit before interest, taxes and amortization Virios Therapeutics|vaxart.com (VXRT) - Profit before payment of interest, taxes and amortization